7.4800
17-5月-24 10:29:46
15 分の遅延
株式
-0.0600
-0.80%
本日の幅
7.4600 - 7.6700
ISIN
FR0012127173
ソース
Cboe
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
16 4 2024 11:00:00 提供 Nasdaq GlobeNewswire
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
10 4 2024 11:00:00 提供 Nasdaq GlobeNewswire
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
02 4 2024 00:30:00 提供 Nasdaq GlobeNewswire
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27 3 2024 12:00:00 提供 Nasdaq GlobeNewswire